Twells Laurie K, Gregory Deborah M, Midodzi William K, Dillon Carla, Kovacs Christopher S, MacDonald Don, Lester Kendra K, Pace David, Smith Chris, Boone Darrell, Murphy Raleen
School of Pharmacy, Memorial University, Health Sciences Centre, 300 Prince Philip Drive, St. John's, NL, A1B 3 V6, Canada.
Faculty of Medicine, Memorial University, Health Sciences Centre, 300 Prince Philip Drive, St. John's, NL, A1B 3 V6, Canada.
BMC Health Serv Res. 2016 Oct 28;16(1):618. doi: 10.1186/s12913-016-1869-5.
In Canada, there has been a disproportionate increase in adults with Class II (BMI 35.0-39.9 kg/m) or Class III obesity (BMI ≥ 40 kg/m) affecting 9 % of Canadians with increases projected. Individuals affected by severe obesity (BMI ≥ 35) are at increased risk of high blood pressure, cardiovascular disease, diabetes, cancer, impaired quality of life, and premature mortality. Bariatric surgery is the most effective treatment for severe obesity. Laparoscopic sleeve gastrectomy (LSG), a relatively new type of bariatric surgery, is growing in popularity as a treatment. The global prevalence of LSG increased from 0 to 37.0 % between 2003 and 2013. In Canada and the US, between 2011 and 2013, the number of LSG surgeries increased by 244 % and LSG now comprises 43 % of all bariatric surgeries. Since 2011, Eastern Health, the largest regional health authority in Newfoundland and Labrador (NL), Canada has performed approximately 100 LSG surgeries annually.
A population-based prospective cohort study with pre and post surgical assessments at 1, 3, 6, 12, 18, 24 months and annually thereafter of patients undergoing LSG. This study will report on short - to mid-term (2-4 years) outcomes. Patients (n = 200) followed by the Provincial Bariatric Surgery Program between 19 and 70 years of age, with a BMI between 35.0 and 39.9 kg/m and an obesity-related comorbidity or with a BMI ≥ 40 kg/m are enrolled. The study is assessing the following outcomes: 1) complications of surgery including impact on nutritional status 2) weight loss/regain 3) improvement/resolution of comorbid conditions and a reduction in prescribed medications 4) patient reported outcomes using validated quality of life tools, and 5) impact of surgery on health services use and costs. We hypothesize a low complication rate, a marked reduction in weight, improvement/resolution of comorbid conditions, a reduction in related medications, improvement in quality of life, and a decrease in direct healthcare use and costs and indirect costs compared to pre-surgery.
Limited data on the impact of LSG as a stand-alone procedure on a number of outcomes exist. The findings from this study will help to inform evidence-based practice, clinical decision-making, and the development of health policy.
在加拿大,患有II类肥胖(体重指数[BMI]为35.0 - 39.9千克/平方米)或III类肥胖(BMI≥40千克/平方米)的成年人数量出现了不成比例的增长,预计这一比例将影响9%的加拿大人。受严重肥胖(BMI≥35)影响的个体患高血压、心血管疾病、糖尿病、癌症、生活质量受损和过早死亡的风险增加。减肥手术是治疗严重肥胖最有效的方法。腹腔镜袖状胃切除术(LSG)是一种相对较新的减肥手术,作为一种治疗方法越来越受欢迎。2003年至2013年间,全球LSG的患病率从0%上升至37.0%。在加拿大和美国,2011年至2013年间,LSG手术的数量增加了244%,目前LSG占所有减肥手术的43%。自2011年以来,加拿大纽芬兰和拉布拉多省(NL)最大的地区卫生当局东部健康每年大约进行100例LSG手术。
一项基于人群的前瞻性队列研究,对接受LSG手术的患者在术后1、3、6、12、18、24个月及此后每年进行术前和术后评估。本研究将报告短期至中期(2 - 4年)的结果。纳入省级减肥手术项目随访的年龄在19至70岁之间、BMI在35.0至39.9千克/平方米之间且患有肥胖相关合并症或BMI≥40千克/平方米的患者(n = 200)。该研究正在评估以下结果:1)手术并发症,包括对营养状况的影响;2)体重减轻/反弹;3)合并症的改善/缓解以及处方药物的减少;4)使用经过验证的生活质量工具得出的患者报告结果;5)手术对医疗服务使用和成本的影响。我们假设与术前相比,并发症发生率低、体重显著减轻、合并症改善/缓解、相关药物减少、生活质量提高、直接医疗使用和成本以及间接成本降低。
关于LSG作为一种独立手术对一系列结果影响的数据有限。本研究的结果将有助于为循证实践、临床决策和卫生政策的制定提供信息。